Tokyo Tape
Sign in
← PeptiDream

Quarterly report · Q2

4587.TEDINET S100RNSH
Period2023-01-01 → 2023-06-30
Filed2023-08-10
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed

Amended by S100S6V5 (2023-11-09).

Key figures · 62
MetricValuePeriodScopeSource row
Revenue¥9.4bn2023-01-01 → 2023-06-30Cons.Revenue IFRS
Revenue¥4.5bn2023-04-01 → 2023-06-30dCons.Revenue IFRS
Revenue¥26.9bn2022-01-01 → 2022-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥5.0bn2022-01-01 → 2022-06-30Cons.Revenue IFRS
Revenue¥4.6bn2022-04-01 → 2022-06-30dCons.Revenue IFRS
Operating income−¥986m2023-01-01 → 2023-06-30Cons.Operating profit loss IFRS
Operating income−¥720m2023-04-01 → 2023-06-30dCons.Operating profit loss IFRS
Operating income−¥1.7bn2022-01-01 → 2022-06-30Cons.Operating profit loss IFRS
Operating income−¥499m2022-04-01 → 2022-06-30dCons.Operating profit loss IFRS
Profit before tax−¥1.1bn2023-01-01 → 2023-06-30Cons.Profit loss before tax IFRS
Profit before tax−¥711m2023-04-01 → 2023-06-30dCons.Profit loss before tax IFRS
Profit before tax¥6.7bn2022-01-01 → 2022-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax−¥1.6bn2022-01-01 → 2022-06-30Cons.Profit loss before tax IFRS
Profit before tax−¥467m2022-04-01 → 2022-06-30dCons.Profit loss before tax IFRS
Net income (owners)−¥729m2023-01-01 → 2023-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)−¥480m2023-04-01 → 2023-06-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥7.6bn2022-01-01 → 2022-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)−¥1.1bn2022-01-01 → 2022-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)−¥303m2022-04-01 → 2022-06-30dCons.Profit loss attributable to owners of parent IFRS
Net income−¥729m2023-01-01 → 2023-06-30Cons.Profit loss IFRS
Net income−¥480m2023-04-01 → 2023-06-30dCons.Profit loss IFRS
Net income¥7.6bn2022-01-01 → 2022-12-31Cons.Profit loss IFRS (5-year summary)
Net income−¥1.1bn2022-01-01 → 2022-06-30Cons.Profit loss IFRS
Net income−¥303m2022-04-01 → 2022-06-30dCons.Profit loss IFRS
Total assets¥57.7bnat 2023-06-30Cons.Assets IFRS
Total assets¥63.9bnat 2022-12-31Cons.Assets IFRS
Total assets¥52.4bnat 2022-06-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥26.7bnat 2023-06-30Cons.Liabilities IFRS
Total liabilities¥31.8bnat 2022-12-31Cons.Liabilities IFRS
Net assets / equity¥31.0bnat 2023-06-30Cons.Equity IFRS
Net assets / equity¥32.0bnat 2022-12-31Cons.Equity IFRS
Net assets / equity¥24.7bnat 2022-06-30Cons.Equity IFRS
Net assets / equity¥25.4bnat 2021-12-31dCons.Equity IFRS
Equity (owners)¥31.0bnat 2023-06-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥32.0bnat 2022-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥24.7bnat 2022-06-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥11.2bnat 2023-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥5.2bnat 2022-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥6.4bnat 2022-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥11.7bnat 2021-12-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥8.8bn2023-01-01 → 2023-06-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow−¥83m2022-01-01 → 2022-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow−¥493m2022-01-01 → 2022-06-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥798m2023-01-01 → 2023-06-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥27.4bn2022-01-01 → 2022-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥26.7bn2022-01-01 → 2022-06-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥2.3bn2023-01-01 → 2023-06-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow¥20.8bn2022-01-01 → 2022-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow¥21.6bn2022-01-01 → 2022-06-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥-5.622023-01-01 → 2023-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥-3.72023-04-01 → 2023-06-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥58.192022-01-01 → 2022-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥-8.722022-01-01 → 2022-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥-2.332022-04-01 → 2022-06-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥-5.622023-01-01 → 2023-06-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥-3.72023-04-01 → 2023-06-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥58.142022-01-01 → 2022-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥-8.722022-01-01 → 2022-06-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥-2.332022-04-01 → 2022-06-30dCons.Diluted earnings loss per share IFRS
Equity ratio53.8%at 2023-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio50.2%at 2022-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio47.0%at 2022-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 22
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-01-01 → 2023-06-30−¥30m
Reconciling Itemsreconcilingrevenue intersegment2023-01-01 → 2023-06-30−¥30m
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue2023-01-01 → 2023-06-30¥1.5bn
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue external2023-01-01 → 2023-06-30¥1.5bn
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentsegment profit2023-01-01 → 2023-06-30−¥1.2bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue2023-01-01 → 2023-06-30¥8.0bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue external2023-01-01 → 2023-06-30¥8.0bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue intersegment2023-01-01 → 2023-06-30¥30m
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentsegment profit2023-01-01 → 2023-06-30¥228m
—segment totalrevenue2023-01-01 → 2023-06-30¥9.5bn
—segment totalrevenue external2023-01-01 → 2023-06-30¥9.4bn
—segment totalrevenue intersegment2023-01-01 → 2023-06-30¥30m
—segment totalsegment profit2023-01-01 → 2023-06-30−¥941m
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue2022-01-01 → 2022-06-30¥1.1bn
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue external2022-01-01 → 2022-06-30¥1.1bn
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentsegment profit2022-01-01 → 2022-06-30−¥1.4bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue2022-01-01 → 2022-06-30¥3.9bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue external2022-01-01 → 2022-06-30¥3.9bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentsegment profit2022-01-01 → 2022-06-30¥114m
—segment totalrevenue2022-01-01 → 2022-06-30¥5.0bn
—segment totalrevenue external2022-01-01 → 2022-06-30¥5.0bn
—segment totalsegment profit2022-01-01 → 2022-06-30−¥1.3bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 634
ItemContextValueUnit
Income tax expense IFRSPrior1YTDDuration-458721000JPY
Income tax expense IFRSCurrentYTDDuration-381918000JPY
Profit loss IFRSPrior1YTDDuration-1132251000JPY
Profit loss IFRSCurrentYTDDuration-729014000JPY
Profit loss attributable to owners of parent IFRSPrior1YTDDuration-1132251000JPY
Profit loss attributable to owners of parent IFRSCurrentYTDDuration-729014000JPY
Profit loss IFRSPrior1YTDDuration-1132251000JPY
Profit loss IFRSCurrentYTDDuration-729014000JPY
Basic earnings loss per share IFRSPrior1YTDDuration-8.72
Basic earnings loss per share IFRSCurrentYTDDuration-5.62
Diluted earnings loss per share IFRSPrior1YTDDuration-8.72
Diluted earnings loss per share IFRSCurrentYTDDuration-5.62
Revenue IFRSPrior1QuarterDuration4604870000JPY
Revenue IFRSCurrentQuarterDuration4462579000JPY
Cost of sales IFRSPrior1QuarterDuration2614238000JPY
Cost of sales IFRSCurrentQuarterDuration2650250000JPY
Gross profit IFRSPrior1QuarterDuration1990632000JPY
Gross profit IFRSCurrentQuarterDuration1812328000JPY
Selling general and administrative expenses IFRSPrior1QuarterDuration1718431000JPY
Selling general and administrative expenses IFRSCurrentQuarterDuration1730399000JPY
Research and development expenses IFRSPrior1QuarterDuration769527000JPY
Research and development expenses IFRSCurrentQuarterDuration798138000JPY
Other income IFRSPrior1QuarterDuration518000JPY
Other income IFRSCurrentQuarterDuration192000JPY
Other expenses IFRSPrior1QuarterDuration2227000JPY
Other expenses IFRSCurrentQuarterDuration3495000JPY
Operating profit loss IFRSPrior1QuarterDuration-499035000JPY
Operating profit loss IFRSCurrentQuarterDuration-719512000JPY
Finance income IFRSPrior1QuarterDuration147944000JPY
Finance income IFRSCurrentQuarterDuration97490000JPY
Finance costs IFRSPrior1QuarterDuration66104000JPY
Finance costs IFRSCurrentQuarterDuration20028000JPY
Share of profit loss of investments accounted for using equity method IFRSPrior1QuarterDuration-50012000JPY
Share of profit loss of investments accounted for using equity method IFRSCurrentQuarterDuration-68968000JPY
Profit loss before tax IFRSPrior1QuarterDuration-467207000JPY
Profit loss before tax IFRSCurrentQuarterDuration-711018000JPY
Income tax expense IFRSPrior1QuarterDuration-164252000JPY
Income tax expense IFRSCurrentQuarterDuration-230805000JPY
Profit loss IFRSPrior1QuarterDuration-302955000JPY
Profit loss IFRSCurrentQuarterDuration-480212000JPY
Profit loss attributable to owners of parent IFRSPrior1QuarterDuration-302955000JPY
Profit loss attributable to owners of parent IFRSCurrentQuarterDuration-480212000JPY
Profit loss IFRSPrior1QuarterDuration-302955000JPY
Profit loss IFRSCurrentQuarterDuration-480212000JPY
Basic earnings loss per share IFRSPrior1QuarterDuration-2.33
Basic earnings loss per share IFRSCurrentQuarterDuration-3.70
Diluted earnings loss per share IFRSPrior1QuarterDuration-2.33
Diluted earnings loss per share IFRSCurrentQuarterDuration-3.70
Profit loss IFRSPrior1YTDDuration-1132251000JPY
Profit loss IFRSCurrentYTDDuration-729014000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2022-12-31pass rounding
balance sheet identityconsolidated 2023-06-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-06-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-06-30pass
statement vs summary · operating cash flowconsolidated 2022-01-01/2022-06-30pass
statement vs summary · operating cash flowconsolidated 2023-01-01/2023-06-30pass
statement vs summary · revenueconsolidated 2022-01-01/2022-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2023-01-01/2023-06-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-06-30pass
statement vs summary · total assetsconsolidated 2022-12-31pass
statement vs summary · total assetsconsolidated 2023-06-30pass